Techniques for prostate biopsy were evaluated by Basque Office for Health Technology Assessment (OSTEBA)

09

Nov 2017

In September, the Basque Office for Health Technology Assessment released a report with results of evaluation different diagnostic techniques for biopsy of prostate. The objective of this work was an assessment of diagnostic effectiveness of biopsies with image fusion (MRI and ultrasound) in comparison to biopsy guided with ultrasound. For this purpose, systematic literature search was performed.

Based on available evidence and expert opinions the technique of software fusion improves the detection of prostate cancer, as well as clinically significant prostate cancer in comparison to prostate biopsies guided by transrectal ultrasound. Thus, prostate biopsy technique with software image fusion may be useful as a first diagnostic option in patients in whom prostatic disease is suspected or as a confirmatory technique in cases in which there is clinical suspicion of prostate cancer despite a result negative in a previous biopsy.

Although the available evidence indicates that prostatic biopsy with software fusion can improve the diagnostic effectiveness of prostate cancer in comparison to the usual method (ultrasound-guided biopsy), there are, nevertheless, important aspects such as experience of the medical staff and the cost-effectiveness ratio that still require evaluation. It was recommended, prior to its possible implementation, to carry out studies that address these aspects and that allow estimating the impact of the implementation of this technique in clinical practice and in the health system.

See full report in Spanish here

Subscribe to our newsletter delivered every second week not to miss important reimbursement information

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more